<u>Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines</u> FUTURE SCIENCE HOLDINGS, INC.

A Nevada Corporation
42 Broadway
Suite 12-311
New York, NY 10004
Company Telephone: 3104083826
Company Email: CEO@IFUTS.COM
SIC Code: 1000

Quarterly Report
For the Period Ending: 006/30/2021
(the "Reporting Period")

As of October 18th, 2021, the number of shares outstanding of our Common Stock was: 96,114,442

As of April 26, 2021, the number of shares outstanding of our Common Stock was: 96,114,442

As of December 31, 2020, the number of shares outstanding of our Common Stock was: 96,114,442

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

1) Name	and address(es) of the issuer and its predecessors (if any)
Yes: □	No: ⊠
Indicate by che	eck mark whether a Change in Control ¹ of the company has occurred over this reporting period:
Yes: □	No: ⊠
Indicate by che	eck mark whether the company's shell status has changed since the previous reporting period:
Yes: □	No: ⊠

The current name of the issuer is Future Science Holdings, Inc., listed below are the dates of any predecessor entities for the past five years and their names:

July 19, 2019 to Present February 19, 2004 to July 19, 2019 April 24, 1988 to February 19, 2004 Future Science Holdings, Inc. White Mountain Titanium Corp. Utah Networking Services, Inc.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

¹ "Change in Control" shall mean any events resulting in:

⁽i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

⁽ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

⁽iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

⁽iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

The Company was incorporated in the State of Nevada on February 19, 2004. The Company, as of September 30, 2019, is active.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

The address(es) of the issuer's principal executive office:

42 Broadway Suite 12-311 New York, NY 10004

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ⊠

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ⊠ No: □

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

On April 24, 2019, the District Court for Clark County, Nevada, entered an order appointing a custodian for the issuer. The Custodianship was terminated on September 18, 2019

2) Security Information

Trading symbol: FUTS

Exact title and class of securities outstanding: Common Stock CUSIP: 36118M 104
Par or stated value: \$0.001

Total shares authorized: 500,000,000 as of date: 06/30/2021 Total shares outstanding: 96,114,442 as of date: 06/30/2021 Number of shares in the Public Float²: 67,334,378 as of date: 06/30/2021 Total number of shareholders of record: 239 as of date: 06/30/2021

All additional class(es) of publicly traded securities (if any):

N/A

Transfer Agent

Name: Issuer Direct Corporation

Phone: 801.272.9294

Email: Julie.Felix@issuerdirect.com

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

Address: 500 Perimeter Park Drive

Suite D

Morrisville, NC 27560

Is the Transfer Agent registered under the Exchange Act?³ Yes: ⊠ No: □

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: \Box

Shares Outstar Recent Fiscal Y Opening Balan Date 01/01/201 Common: 96,1	/ear End:12/3 ce l9		*Right-click the rows below and select "Insert" to add rows as needed.								
Preferred: 100 Date of Transaction	Transacti on type (e.g. new issuance, cancellati on, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securitie s	Value of shares issued (\$/per share) at Issuance	Were the shar es issu ed at a disc ount to mark et price at the time of issu ance ? (Yes/ No)	Individual / Entity Shares were issued to (entities must have individual with voting / investme nt control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricte d as of this filing.	Exemp tion or Registr ation Type.		
06/02/2019	New Issuance	900,000	Preferred A Shares	\$.001	no	Bridgeview Capital Partners, LLC/	Payment of Company Debts	Restricted	N/A		

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

	Michael Dobbs	
Shares Outstanding on Date of Thi Report:		
Ending Balance		
Date 03/31/2021		
Common: 96,114,442		
Preferred: 900,100		

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

A. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstandin g Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrue d (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
7/2/2019	\$42,081	\$33,000.00	\$9,081	6/23/2020	\$.001 conversion rate, not to exceed 9.9% of outstanding shares for each conversion	Watercorp, Inc. Casey Jensen	Debt paid on behalf of company
12/16/2019	\$160,158	\$145,056	\$15,102	12/16/2020	50% of lowest price for the twenty days prior to conversion	Interspace Global, Inc Jianfei Wu	Loan to company
06/30/2020	17,154	17,154	0	Due upon demand	Unsecured, no- interest bearing, due upon demand	Luis Rodriguez	Loan to company

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

☑ U.S. GAAP

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Rachel Boulds

Title: CPA

Relationship to Issuer: Outside Service Provider

Financial statements described below are for March 31,2021.

- C. Balance sheet;
- D. Statement of income:
- E. Statement of cash flows:
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Future Science Holdings, Inc. is a multi-strategy technology company with a focus on developing or acquiring control and/or hold companies with synergies in technology.

B. Please list any subsidiaries, parents, or affiliated companies.

None

C. Describe the issuers' principal products or services.

Currently, the Company is searching/researching for new investment opportunities, with a principal business objective of starting up a new business, acquiring all or part of an existing business and/or a combination with an existing business in the technology sector.

6) Issuer's Facilities

The Company leases office space at 42 Broadway, Suite 13-311, New York, NY 10004

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Luis Rodiguez	CEO, Secretary, Treasurer, Director	New York, NY	0			
Manhattan Capital LLC/Casey Jensen	Majority Shareholder	9350 Wilshire Blvd. Suite 203 Beverly Hills, CA 90212	900,000	Preferred	100% Convertible Preferred Series C Stock	

8) Legal/Disciplinary History

- A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:
 - 1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: N/A

Firm: Address 1: Address 2: Phone: Email:

Accountant or Auditor

Name: N/A

Firm: Address 1: Address 2: Phone: Email:

Investor Relations

Name: N/A

Firm: Address 1: Address 2: Phone: Email:

Other Service Providers

Provide the name of any other service provider(s) that **that assisted**, **advised**, **prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: Rhonda Keaveney
Firm: SCC Transfer, LLC

Nature of Services: Compliance Address 1: PO Box 26496

Address 2: Scottsdale, AZ 85255

Phone: 602.793.8058

Email: rhonda@scctransferllc.com

10) Issuer Certification

- I, Luis Rodriguez, certify that:
 - 1. I have reviewed this 06/30/2021 quarterly report of Future Science Holdings Inc.;

- 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
- 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 20, 2021

/s/ Luis Rodriguez

Principal Financial Officer:

- I, Luis Rodriguez, certify that:
 - 1. I have reviewed this 06/30/2021 quarterly report of Future Science Holdings Inc.;
 - 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
 - 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 20,2021

/s/ Luis Rodriguez

FUTURE SCIENCE HOLDINGS, INC. BALANCE SHEETS

(Unaudited)

Current Assets: Cash		June 30, 2021	December 31, 2020		
Cash \$ 73 \$ 623 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities: Accrued interest \$ 34,360 \$ 24,183 Convertible notes payable 178,056 178,056 Loan payable - related party 37,904 1,540 Loan payable 15,860 220,933 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; no shares issued and outstanding, respectively - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding, respectively - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding respectively - - Series C Preferred Stock, par value \$0.001, \$0,000,000 shares authorized; no shares issued and outstanding respectively 900 900 Common Stock, par value \$0.001, \$5,	ASSETS				
Total Assets	Current Assets:				
Current Liabilities: Accrued interest \$ 34,360 \$ 24,183 Convertible notes payable 178,056 178,056 Loan payable - related party 37,904 17,154 Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; no shares issued and outstanding, respectively - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding, respectively - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding -	Cash	\$ 73	\$	623	
Current Liabilities: 34,360 \$ 24,183 Convertible notes payable 178,056 178,056 Loan payable – related party 37,904 17,154 Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; - - - Series A Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding, respectively - - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 61,491,171 Accumulated defi	Total Assets	\$ 73	\$	623	
Current Liabilities: 34,360 \$ 24,183 Convertible notes payable 178,056 178,056 Loan payable – related party 37,904 17,154 Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; - - - Series A Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding, respectively - - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 61,491,171 Accumulated defi					
Accrued interest \$ 34,360 \$ 24,183 Convertible notes payable 178,056 178,056 Loan payable – related party 37,904 17,154 Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 5,000,000 shares authorized; 90,114,442 96,114 96,114 shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) <	LIABILITIES AND STOCKHOLDERS' DEFICIT				
Accrued interest \$ 34,360 \$ 24,183 Convertible notes payable 178,056 178,056 Loan payable – related party 37,904 17,154 Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 5,000,000 shares authorized; 90,114,442 96,114 96,114 shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) <					
Convertible notes payable 178,056 178,056 Loan payable – related party 37,904 17,154 Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; - - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 500,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit <	Current Liabilities:				
Loan payable – related party 37,904 17,154 Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 500,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,808,495) Total Stockholders' Deficit (221,787) (220,310)	Accrued interest	\$ 34,360	\$	24,183	
Loan payable 1,540 1,540 Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (220,310)		178,056		178,056	
Total Current Liabilities 251,860 220,933 Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; - - 100 shares issued and outstanding, respectively - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)		37,904		17,154	
Total Liabilities 251,860 220,933 Commitments and contingencies - - Stockholders' Deficit: - - Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding - - Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively - - Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,808,495) Total Stockholders' Deficit (251,787) (220,310)	Loan payable	1,540		1,540	
Commitments and contingencies	Total Current Liabilities	251,860		220,933	
Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding authorized; 96,114,442 shares issued and outstanding 406,114 Additional paid-in capital Additional paid-in capital 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (220,310)	Total Liabilities	 251,860		220,933	
Stockholders' Deficit: Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 and no stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 shares issued and outstanding 96,114 Additional paid-in capital Additional paid-in capital 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit					
Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,114,442 shares issued and outstanding 96,114 Additional paid-in capital Additional paid-in capital 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit	Commitments and contingencies	-		-	
Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares issued and outstanding Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,114,442 Shares issued and outstanding 96,114 Additional paid-in capital Additional paid-in capital 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit					
issued and outstanding Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 906,114,442 shares issued and outstanding Additional paid-in capital Additional paid-in capital Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (220,310)	Stockholders' Deficit:				
Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized; 100 shares issued and outstanding, respectively Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900,000 shares authorized; 900,000 shares authorized; 96,114,442 shares issued and outstanding 96,114 Additional paid-in capital Additional paid-in capital Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (220,310)	Preferred Stock, par value \$0.001, 75,499,900 shares authorized; no shares				
100 shares issued and outstanding, respectively Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 shares issued and outstanding 96,114 Additional paid-in capital Additional paid-in capital 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (220,310)		-		-	
Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no shares issued and outstanding Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 shares issued and outstanding Additional paid-in capital Accumulated deficit Total Stockholders' Deficit Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900 900 900 900 901 901 901 901	Series A Preferred Stock, par value \$0.001, 19,000,100 shares authorized;				
shares issued and outstanding - - Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 Shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)		-		-	
Series C Preferred Stock, par value \$0.001, 5,000,000 shares authorized; 900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 Shares issued and outstanding Additional paid-in capital Accumulated deficit 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)	Series B Preferred Stock, par value \$0.001, 500,000 shares authorized; no				
900,000 and no shares issued and outstanding, respectively 900 900 Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)		-		-	
Common Stock, par value \$0.001, 450,000,000 shares authorized; 96,114,442 96,114 96,114 shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)					
shares issued and outstanding 96,114 96,114 Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)		900		900	
Additional paid-in capital 61,491,171 61,491,171 Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)					
Accumulated deficit (61,839,972) (61,808,495) Total Stockholders' Deficit (251,787) (220,310)	- C	/		/	
Total Stockholders' Deficit (251,787) (220,310)					
	1100 00110101010 0011010	 			
Total Liabilities and Stockholders' Deficit \$ 73 \$ 623		(251,787)		(220,310)	
	Total Liabilities and Stockholders' Deficit	\$ 73	\$	623	

FUTURE SCIENCE HOLDINGS, INC. STATEMENTS OF OPERATIONS (Unaudited)

	For the Three Jun	Montle 30,	ns Ended	For the Six Months Ended June 30,				
	 2021		2020	2021	2020			
Operating Expenses:	_							
General and administrative	\$ 10,320	\$	1,247	\$ 21,299	\$	8,769		
Total operating expenses	10,320		1,247	21,299		8,769		
Loss from operations	\$ (10,320)	\$	(1,247)	\$ (21,299)	\$	(8,769)		
Other expense:								
Interest expense	(5,097)		(5,098)	(10,178)		(10,195)		
Total other expense	(5,097)		(5,098)	(10,178)		(10,195)		
Net Loss	\$ (15,417)	\$	(6,345)	\$ (31,477)	\$	(18,964)		
Loss per share, basic and diluted	\$ (0.00)	\$	(0.00)	\$ (0.00)	\$	(0.00)		
Weighted average common shares outstanding, basic and diluted	96,114,442		96,114,442	96,114,442		96,114,442		

FUTURE SCIENCE HOLDINGS, INC. STATEMENTS OF STOCKHOLDERS' DEFICIT

For the Three and Six Months Ended June 30, 2020 and 2021 (Unaudited)

	Sei Preferi	ries A red Sto	ock	Ser Prefer	ries B red St		Series C Preferred Sto	ck	Commor	ı Sto	ck	Paid in Capital	Accumulated Deficit	Total
Balance, December 31, 2019	100	\$	-	-	\$	-	900,000 \$	900	96,114,442	\$	96,114	\$ 61,491,171	\$ (61,770,001)	\$ (181,816)
Net loss								-	-			 	(12,619)	(12,619)
Balance, March 31, 2020	100		-	-		-	900,000	900	96,114,442		96,114	61,491,171	(61,782,620)	(194,435)
Net loss						_		_			-	_	(6,345)	(6,345)
Balance, June 30, 2020	100	\$	-		\$		900,000 \$	900	96,114,442	\$	96,114	\$ 61,491,171	\$ (61,788,965)	\$ (200,780)

	Ser Prefer	ries A red Sto	ock	Ser Preferr	ies B ed Stoc	:k	Series C Preferred S		Common Stock		ck	Paid in Capital		
Balance, December 31, 2020	100	\$	-	-	\$	-	900,000 \$	900	96,114,442	\$	96,114	\$ 61,491,171	\$ (61,808,495)	\$ (220,310)
Net loss			-					-			<u>-</u>		(16,060)	(16,060)
Balance, March 31, 2021	100		-	-		-	900,000 \$	900	96,114,442		96,114	61,491,171	(61,824,555)	(236,370)
Net loss			-					-					(15,417)	(15,417)
Balance, June 30, 2021	100	\$			\$		900,000 \$	900	96,114,442	\$	96,114	\$ 61,491,171	\$ (61,839,972)	\$ (251,787)

FUTURE SCIENCE HOLDINGS, INC. STATEMENTS OF CASH FLOWS (Unaudited)

	Fo	For the Six Months Ended June 30					
		2021		2020			
Cash flows from operating activities:							
Net Loss	\$	(31,477)	\$	(18,964)			
Adjustments to reconcile net loss to net cash used in operating activities:							
Changes in Operating Assets and Liabilities:							
Accrued interest		10,177		10,195			
Net cash used in operating activities		(21,300)		(8,769)			
Cash flows from investing activities:							
Cash flows from financing activities:							
Proceeds from loans		-		1,540			
Proceeds from loans – related party		20,750		7,254			
Net cash provided by financing activities		20,750		8,794			
Net change in cash		(550)		24			
Cash, beginning of period		623		-			
	Φ	72	Ф	25			
Cash, end of period	\$	73	\$	25			
Supplemental disclosure of cash flow information:							
Cash paid for taxes	\$		\$	-			
Cash paid for interest	\$		\$	-			

FUTURE SCIENCE HOLDINGS, INC. NOTES TO UNAUDITED FINANCIAL STATEMENTS June 30, 2021 (Unaudited)

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

Future Science Holdings, Inc. (the "Company") (formerly White Mountain Titanium Corp.) was incorporated on February 19, 2004 under the laws of the State of Nevada. On April 24, 2019, the District Court for Clark County, Nevada, entered an order appointing a custodian for White Mountain Titanium Corp. On June 28, 2019, the Custodian appointed a new interim officer and a sole director, Luis Rodriguez. On July 2, 2019, the Custodian filed a Certificate of Designation with the Nevada Secretary of State to authorize 5,000,000 shares of Preferred C Stock. The Custodian issued 900,000 shares of the Convertible Preferred Series C to Bridgeview Capital Partners, LLC. These shares represent a majority of the voting power of the Company, with each one share, holding 1,000 votes of common stock. On September 18, 2019, the Custodianship was terminated by the District Court for Clark County, Nevada.

The Company filed a Certificate of Amendment with the Nevada Secretary of State on July 19, 2019 to change its name to Future Science Holdings, Inc.

On September 23, 2019, FINRA approved a corporate action to change the name of the company to Future Science Holdings, Inc.

Future Science Holdings, Inc. is a multi-strategy technology company with a focus on developing or acquiring control and/or hold companies with synergies in technology. Currently, the Company is searching/researching for new investment opportunities, with a principal business objective of starting up a new business, acquiring all or part of an existing business and/or a combination with an existing business in the technology sector.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

Cash equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of June 30, 2021 or December 31, 2020.

Recently issued accounting pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

NOTE 3 - GOING CONCERN

The Company's unaudited financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not established any source of revenue to cover its operating costs and has an accumulated deficit. These conditions raise substantial doubt about the company's ability to continue as a going concern. The Company will engage in limited activities without incurring significant liabilities that must be satisfied in cash until a source of funding is secured. The Company will offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders.

NOTE 4 – CONVERTIBLE NOTES PAYABLE

On June 23, 2019, the Company entered into a convertible promissory note with Bridgeview Capital Partners, LLC for \$33,000. The note accrues interest at 18% per annum, is convertible into common stock at \$0.001 per share and is due on demand. On July 2, 2019, Bridgeview Capital Partners, LLC assigned the note and accrued interest to Wagercorp, Inc., a non-related third party. As of June 30, 2021 and December 31, 2020, there is \$12,026 and \$9,081, respectively, of accrued interest due on this note.

NOTE 5 – RELATED PARTY TRANSACTION

On December 16, 2019, the Company entered into a convertible promissory note with Interspace Global, Inc. for \$145,056. The note accrues interest at 10% per annum and is due on or before December 16, 2020. If not paid on or before the due date the note is convertible into shares of common stock at the rate of 50% of the lowest close price for the twenty days prior to the conversion date. As of June 30, 2021 and December 31, 2020, there is \$22,334 and \$15,102, respectively, of accrued interest due on this note.

As of June 30, 2021, Luis Rodriguez, CEO, has advanced the Company \$33,154 to pay for general operating expenses. The advance is unsecured, non-interest bearing and due on demand.

NOTE 6 – PREFERRED STOCK

The Company has 100,000,000 shares of authorized preferred stock, par value \$0.001. Of those there are the following designations.

The Company has 19,000,100 shares designated Series A Convertible Preferred Stock. One share of Series A preferred is convertible into common stock at the option of the holder at \$0.12. The Series A preferred holders are entitled to votes equal to the number of common shares to which they can convert, and they are entitled to dividends. There are 100 shares of Series A Convertible Preferred Stock outstanding as of June 30, 2021.

The Company has 500,000 shares designated Series B Convertible Preferred Stock. One share of Series B preferred is convertible into 1,000 shares of common stock at the option of the holder. There are no shares of Series B Convertible Preferred Stock outstanding as of June 30, 2021.

The Company has 5,000,000 Convertible Preferred Series C shares authorized. One share of Series C preferred is convertible into 1,000 shares of common stock at the option of the holder. The Series C preferred holders are entitled to 1,000 votes per one share held and are not entitled to dividends. There are 900,000 shares of Series C Convertible Preferred Stock outstanding as of June 30, 2021.

NOTE 7 - SUBSEQUENT EVENTS

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.